Considering that psychosis symptoms are often exacerbated during the perimenstrual phase [113], antipsychotic (prolactin-sparing, e.g., quetiapine) augmentation with SERMs (e.g., raloxifene) and/or intranasally administered OXT may act as a better alternative than incremented antipsychotic dosage in treatment-resistant schizophrenia. The gene discussed is PRL; the disease is schizophrenia.